Get the Stockscreener App
38.94
2.03%
0.79
Verona Pharma Plc Adr stock is traded at $38.94, with a volume of 640.40K.
It is up +2.03% in the last 24 hours and up +21.60% over the past month.
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
See More
Previous Close:
$38.15
Open:
$39.05
24h Volume:
640.40K
Relative Volume:
0.61
Market Cap:
$3.20B
Revenue:
-
Net Income/Loss:
$-125.45M
P/E Ratio:
-69.54
EPS:
-0.56
Net Cash Flow:
$-53.89M
1W Performance:
+15.60%
1M Performance:
+21.60%
6M Performance:
+148.08%
1Y Performance:
+153.24%
1-Day Range:
$37.80
$39.40
1-Week Range:
$31.60
$39.40
52-Week Range:
$11.39
$39.40
Verona Pharma Plc Adr Stock (VRNA) Company Profile
Name
Verona Pharma Plc Adr
Sector
Industry
Phone
011-44-0-2032834200
Address
3 MORE LONDON RIVERSIDE, LONDON
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-23 | Resumed | Jefferies | Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-26-22 | Initiated | Piper Sandler | Overweight |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Jefferies | Buy |
| Aug-10-20 | Initiated | Canaccord Genuity | Buy |
| Apr-18-19 | Initiated | BTIG Research | Buy |
View All
Verona Pharma Plc Adr Stock (VRNA) Latest News
Earnings call: Verona Pharma reports Q3 results, optimistic on Ohtuvayre - Investing.com
Earnings call: Verona Pharma reports Q3 results, optimistic on Ohtuvayre By Investing.com - Investing.com UK
Exxon Mobil, Constellation Lead Afternoon Market Cap Stock Movers on Monday - Investing.com Nigeria
Verona Pharma ADR earnings matched, revenue topped estimates By Investing.com - Investing.com UK
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Verona Pharma CFO Mark Hahn sells shares worth $632,760 - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $633,895 - Investing.com India
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Barchart
Verona Pharma CEO David Zaccardelli sells $2.25 million in shares - Investing.com India
Verona Pharma CEO David Zaccardelli sells $2.25 million in shares By Investing.com - Investing.com South Africa
Verona Pharma CFO Mark Hahn sells shares worth $2.3 million By Investing.com - Investing.com South Africa
Verona Pharma CFO Mark Hahn sells shares worth $2.3 million - Investing.com India
Market Insights: Verona Pharma Plc ADR (VRNA)’s Notable Drop of -0.55, Closing at 34.07 - The Dwinnex
Verona Pharma Plc ADR [VRNA] Insider Activity: An Update for Investors - Knox Daily
Phathom Pharmaceuticals Inc [PHAT] Investment Appeal on the Rise - Knox Daily
Verona Pharma Plc ADR (VRNA) stock: A year of ups and downs - US Post News
VRNA Shares Experience Decline in Value - Knox Daily
Financial Metrics Exploration: Understanding Verona Pharma Plc ADR (VRNA) Through Ratios - The Dwinnex
A stock that deserves closer examination: Verona Pharma Plc ADR (VRNA) - US Post News
Wells Fargo gives an Overweight recommendation for Verona Pharma Plc ADR (VRNA) - Knox Daily
Verona Pharma Plc ADR’s (NASDAQ: VRNA) Stock Forecast: Increase To $38 In A Year - Stocks Register
Prepare Yourself for Liftoff: Verona Pharma Plc ADR (VRNA) - SETE News
Verona Pharma Plc ADR [VRNA] stock for 2,254,320 USD was sold by ZACCARDELLI DAVID - Knox Daily
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains? - Yahoo Finance
Cactus Inc [WHD] Records 50-Day SMA of $59.34 - Knox Daily
Verona Pharma stock soars to all-time high of $30.76 By Investing.com - Investing.com South Africa
Piper Sandler maintains Overweight rating on Verona Pharma shares By Investing.com - Investing.com South Africa
Sea Limited Sponsored ADR (SE) Stock Moves -0.17%: What You Should Know - Yahoo Finance
Verona Pharma stock soars to all-time high of $30.76 - Investing.com
VRNA’s Stock Market Adventure: 58.43% YTD Growth Amidst Volatility - The InvestChronicle
Atour Lifestyle Holdings Limited Sponsored ADR (ATAT) Moves 6.2% Higher: Will This Strength Last? - Yahoo Finance
MINISO Group Holding Limited Unsponsored ADR (MNSO) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Verona Pharma Plc ADR (VRNA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Investing in Verona Pharma Plc ADR (VRNA) might be a great opportunity, but the stock is a bit overvalued - US Post News
Upcoming Stock Splits This Week (September 30 to October 4) – Stay Invested - Yahoo Finance
Investing in Verona Pharma Plc ADR (VRNA) Is Getting More Attractive - Knox Daily
Li Auto Inc. Sponsored ADR (LI) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Verona Pharma's SWOT analysis: stock soars on Ohtuvayre approval, COPD market potential - Investing.com India
Market Momentum Report: Verona Pharma Plc ADR (VRNA)’s Positive Close at 28.76 - The Dwinnex
Verona Pharma's SWOT analysis: stock soars on Ohtuvayre approval, COPD market potential By Investing.com - Investing.com South Africa
Why Sea Limited Sponsored ADR (SE) Dipped More Than Broader Market Today - Yahoo Finance
Verona Pharma Plc ADR [NASDAQ: VRNA] Sees Decrease in Stock Value - Knox Daily
Atour Lifestyle Holdings Limited Sponsored ADR (ATAT) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Sea Limited Sponsored ADR (SE) Outperforms Broader Market: What You Need to Know - Yahoo Finance
The growth track for Verona Pharma Plc ADR (VRNA) has changed recently - SETE News
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - Yahoo Finance
Are You Looking for a Top Momentum Pick? Why Taylor Wimpey PLC Unsponsored ADR (TWODY) is a Great Choice - Yahoo Finance
Is America Movil, S.A.B. de C.V. Unsponsored ADR (AMX) Stock Undervalued Right Now? - Yahoo Finance
Verona Pharma Plc ADR [VRNA] President and CEO makes an insider sale of 600,000 shares worth $2.25 million. - Knox Daily
Investor’s Delight: Verona Pharma Plc ADR (VRNA) Closes Weak at 29.60, Down -1.30 - The Dwinnex
Does Verona Pharma Plc ADR (NASDAQ: VRNA) Still Look Hot This Week? - Stocks Register
Verona Pharma Plc Adr Stock (VRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):